🇺🇸 FDA
Patent

US 11739297

Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor

granted A61KA61K2239/13A61K2239/21

Quick answer

US patent 11739297 (Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor) held by Carisma Therapeutics Inc. expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Carisma Therapeutics Inc.
Grant date
Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2239/13, A61K2239/21, A61K2239/22, A61K38/00